SCHEMBL2587052

SCHEMBL2587052

OC[C@H]1CC[C@@H](c2c(F)cc(F)cc2F)N1

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TRPM5 Q9NZQ8 6/20 0.34
TRPM4 Q8TD43 2/20 0.34
APOL1 O14791 2/20 0.32
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2585809 0.76 TRPM5 (0.33) TRPM5TRPM4
SCHEMBL22040875 0.74 KCNH2 (0.46) TRPM5TRPM4
SCHEMBL22040882 0.74 KCNH2 (0.46) TRPM5TRPM4
SCHEMBL23878267 0.74 KCNH2 (0.46) TRPM5TRPM4
SCHEMBL25256114 0.74 KCNH2 (0.46) TRPM5TRPM4
SCHEMBL23878268 0.74 KCNH2 (0.46) TRPM5TRPM4
SCHEMBL22040870 0.74 KCNH2 (0.46) TRPM5TRPM4
SCHEMBL24220441 0.72 TRPM5 (0.49) TRPM5TRPM4
SCHEMBL20564870 0.72 TRPM5 (0.49) TRPM5TRPM4
SCHEMBL12943765 0.72 TRPM5 (0.35) TRPM5TRPM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1953158-B1 BICYCLIC CINNAMIDE COMPOUND EISAI R&D MAN CO LTD (JP) 2012-09-12 EP disclosed
US-8048878-B2 Two cyclic cinnamide compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-11-01 US disclosed
US-20090181945-A1 TWO CYCLIC CINNAMIDE COMPOUND KIMURA TEIJI 2009-07-16 US disclosed
EP-1953158-A1 BICYCLIC CINNAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2008-08-06 EP disclosed
US-20070117839-A1 Two cyclic cinnamide compound EISAI R&D MANAGEMENT CO., LTD. 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181945-A1 TWO CYCLIC CINNAMIDE COMPOUND APP, BACE1, PSEN1 TRPM5 2497/4885TRPM4 2949/4885APOL1 109/4885
US-20070117839-A1 Two cyclic cinnamide compound APP, BACE1, PSEN1 TRPM5 2497/4885TRPM4 2949/4885APOL1 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.